Publications by authors named "Dirk Garmann"

Claim this Profile
P
Population Pharmacokinetics of Asundexian in People at Risk for Thromboembolic/Cardiovascular Events.
Ashraf Yassen, Friederike Kanefendt, Jochen Zisowsky, Astrid Broeker, Hardi Mundl, Dirk Garmann

CPT Pharmacometrics Syst Pharmacol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Model-Based Benefit/Risk Analysis for the Copanlisib Intermittent Dosing Regimen.
Peter N Morcos, Jonathan Moss, Josh Veasy, Florian Hiemeyer, Barrett H Childs, Dirk Garmann

Clin Pharmacol Ther· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of covariate effects in item response theory models.
Gustaf J Wellhagen, Ashraf Yassen, Dirk Garmann, Astrid Bröker, Alexander Solms

CPT Pharmacometrics Syst Pharmacol· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Item response theory analysis of daytime sleepiness as a symptom of obstructive sleep apnea.
Gustaf J Wellhagen, Mats O Karlsson, Maria C Kjellsson, Dirk Garmann, Astrid Bröker

CPT Pharmacometrics Syst Pharmacol· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics and pharmacodynamics of finerenone in patients with chronic kidney disease and type 2 diabetes: Insights based on FIGARO-DKD and FIDELIO-DKD.
Thomas Eissing, Sebastiaan Camiel Goulooze, Paul van den Berg, Martijn van Noort, Martijn Ruppert, Dirk Garmann

Diabetes Obes Metab· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Copanlisib population pharmacokinetics from phase I-III studies and exposure-response relationships in combination with rituximab.
Peter N Morcos, Jonathan Moss, Rupert Austin, Florian Hiemeyer, Pier Luigi Zinzani, Dirk Garmann

CPT Pharmacometrics Syst Pharmacol· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessing QTc Effects of Vericiguat Using Two Different Concentration-QTc Modeling Approaches.
Hauke Ruehs, Alexander Solms, Matthias Frei, Corina Becker, Maria E Trujillo, Dirk Garmann

Clin Pharmacokinet· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Model-informed approach to support pediatric dosing for the pan-PI3K inhibitor copanlisib in children and adolescents with relapsed/refractory solid tumors.
Peter N Morcos, Jan Schlender, Rolf Burghaus, Jonathan Moss, Adam Lloyd, Dirk Garmann

Clin Transl Sci· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Population Pharmacokinetics of Nifurtimox in Adult and Pediatric Patients With Chagas Disease.
Ibrahim Ince, Klaas Prins, Stefan Willmann, Gabriele Sutter, Eva Hanze, Dirk Garmann

J Clin Pharmacol· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Finerenone Dose-Exposure-Response for the Primary Kidney Outcome in FIDELIO-DKD Phase III: Population Pharmacokinetic and Time-to-Event Analysis.
Paul van den Berg, Martijn Ruppert, Emir Mesic, Nelleke Snelder, Andreas Seelmann, Dirk Garmann

Clin Pharmacokinet· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Finerenone Dose-Exposure-Serum Potassium Response Analysis of FIDELIO-DKD Phase III: The Role of Dosing, Titration, and Inclusion Criteria.
Sebastiaan Camiel Goulooze, Nelleke Snelder, Andreas Seelmann, Andrea Horvat-Broecker, Meike Brinker, Dirk Garmann

Clin Pharmacokinet· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Population Pharmacokinetics and Pharmacodynamics of Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction.
Hauke Ruehs, Dagmar Klein, Matthias Frei, Joachim Grevel, Rupert Austin, Dirk Garmann

Clin Pharmacokinet· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
NT-proBNP Qualifies as a Surrogate for Clinical End Points in Heart Failure.
Walter Schmitt, Hauke Rühs, Rolf Burghaus, Christian Diedrich, Sulav Duwal, Dirk Garmann

Clin Pharmacol Ther· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Associations between model-predicted rivaroxaban exposure and patient characteristics and efficacy and safety outcomes in the prevention of venous thromboembolism.
Isabel Reinecke, Alexander Solms, Stefan Willmann, Theodore E Spiro, Gary Peters, Dirk Garmann

J Thromb Thrombolysis· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Associations between model-predicted rivaroxaban exposure and patient characteristics and efficacy and safety outcomes in the treatment of venous thromboembolism.
Alexander Solms, Stefan Willmann, Isabel Reinecke, Theodore E Spiro, Gary Peters, Dirk Garmann

J Thromb Thrombolysis· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Relationship between factor VIII activity, bleeds and individual characteristics in severe hemophilia A patients.
João A Abrantes, Alexander Solms, Dirk Garmann, Elisabet I Nielsen, Siv Jönsson

Haematologica· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Favorable Pharmacokinetic Characteristics of Extended-Half-Life Recombinant Factor VIII BAY 94-9027 Enable Robust Individual Profiling Using a Population Pharmacokinetic Approach.
Alexander Solms, Alfonso Iorio, Maurice J Ahsman, Peter Vis, Anita Shah, Dirk Garmann

Clin Pharmacokinet· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Population Pharmacokinetic and Exposure-Response Analysis of Finerenone: Insights Based on Phase IIb Data and Simulations to Support Dose Selection for Pivotal Trials in Type 2 Diabetes with Chronic Kidney Disease.
Nelleke Snelder, Roland Heinig, Henk-Jan Drenth, Amer Joseph, Peter Kolkhof, Dirk Garmann

Clin Pharmacokinet· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bayesian Forecasting Utilizing Bleeding Information to Support Dose Individualization of Factor VIII.
João A Abrantes, Alexander Solms, Dirk Garmann, Elisabet I Nielsen, Siv Jönsson

CPT Pharmacometrics Syst Pharmacol· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Enhancing the Quality of Rivaroxaban Exposure Estimates Using Prothrombin Time in the Absence of Pharmacokinetic Sampling.
Alexander Solms, Matthias Frede, Scott D Berkowitz, Anne Hermanowski-Vosatka, Dagmar Kubitza, Dirk Garmann

CPT Pharmacometrics Syst Pharmacol· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Influence of model-predicted rivaroxaban exposure and patient characteristics on efficacy and safety outcomes in patients with acute coronary syndrome.
Liping Zhang, Xiaoyu Yan, Partha Nandy, Stefan Willmann, Keith A A Fox, Dirk Garmann

Ther Adv Cardiovasc Dis· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An Integrated Population Pharmacokinetic Analysis to Characterize Levonorgestrel Pharmacokinetics After Different Administration Routes.
Isabel Reinecke, Birte Hofmann, Emir Mesic, Henk-Jan Drenth, Dirk Garmann

J Clin Pharmacol· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Integrated Population Pharmacokinetic Analysis of Rivaroxaban Across Multiple Patient Populations.
Stefan Willmann, Liping Zhang, Matthias Frede, Dagmar Kubitza, Wolfgang Mueck, Dirk Garmann

CPT Pharmacometrics Syst Pharmacol· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Improved Pharmacokinetics with BAY 81-8973 Versus Antihemophilic Factor (Recombinant) Plasma/Albumin-Free Method: A Randomized Pharmacokinetic Study in Patients with Severe Hemophilia A.
Anita Shah, Alexander Solms, Dirk Garmann, Yvonne Katterle, Verzhiniya Avramova

Clin Pharmacokinet· September 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Enhancing lipophilicity as a strategy to overcome resistance against platinum complexes?
Irina Buss, Dirk Garmann, Mathea S Galanski, Günther Weber, Ganna V Kalayda

J Inorg Biochem· May 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis